35 results about "Neuroblast" patented technology

The invention relates to a new purpose of protein kinase Mnk2a. According to the invention, the Mnk2a can be identified by a western means, the phosphorylation of Alpha-synuclein129 site serine through an extracellular signal-regulated kinase (ERK) signal passage, and at the same time, the effect that in human neuroblast oncocyte (SH-5Y-5Y) nucleuses, Mnk2a can intensify the formation of Alpha-synuclein granular aggregates similar to Lewy bodies is detected by a cell immunofluorescence means. The further basis and the action mechanism can be provided for the full study of disease generation pathogenesis of parkinson's diseases (PD).

The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.

An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: Musashi1 (Msi1); Ngn2; Msi1 and Ngn2; Msi1 and methyl-CpG binding domain protein 2 (MBD2); Ngn2 and MBD2; Msi1, Ngn2 and MBD2; Achaete-Scute Homolog 1 (Ascl1); Msi1, Ngn2 and Ascl1; Msi1, Ngn2, MBD2 and Ascl1; Sox2; Msi1, Ngn2 and Sox2; and Msi1, Ngn2, MBD2 and Sox2; wherein the expression vector is transiently expressed.

A method for producing a neuroblast and a cellular composition comprising an enriched population of neuroblast cells is provided. Also disclosed are methods for identifying compositions which affect neuroblasts and for treating a subject with a neuronal disorder, and a culture system for the production and maintenance of neuroblasts.

The invention belongs to the technical field of stem cell induction differentiation, particularly relates to an inducer and an induction medium, and discloses an inducer and induced differentiation complete medium for inducing mesenchymal stem cells into nerve cells. The inducer for inducing the mesenchymal stem cells into the nerve cells comprises resveratrol, icariin, hydrocortisone, VEGF, IGF-I and EPO. Every one thousand milliliters of the induced differentiation complete medium for inducing the mesenchymal stem cells into nerve cells comprises 30-50 micromoles of resveratrol, 5-10 micromoles of icariin, 5-10 micromoles of hydrocortisone, 10-20 micrograms of VEGF, 5-10 micrograms of IGF-I, 2-5 micrograms of EPO and the balance mesenchymal stem cell serum-free complete media. According to the induced differentiation complete medium for inducing the mesenchymal stem cells into the nerve cells, the traditional Chinese medicine ingredients of resveratrol and icariin are combined with hydrocortisone and the growth factors of VEGF, IGF-I and EPO to synergistically induce the mesenchymal stem cells to be directionally differentiated into the nerve cells, and the selected induction components are all free of poison, high in induction efficiency, short in induction time, good in activity of the nerve cells obtained through induction, free of rejection after cell transplantation, free of ethical issues and high in safety.

The present invention belongs to the field of cell transplantation. Particularly, the present invention provides a method of producing neurons for treating injuries with the loss of neuron function from stem cells, wherein the stem cell is a human derived mesenchymal stem cell, preferably human derived placental mesenchymal stem cell, bone marrow mesenchymal stem cell, adipose mesenchymal stem cell and liver mesenchymal stem cell. The present invention also provides the uses of said method and the nerve cells produced by said method in the preparation of medicines for treating injuries with the loss of neuron function and in the treatment of injuries with the loss of neuron function. The present invention further provides a method of treating injuries with the loss of neuron function.